CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 174 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2015. The put-call ratio across all filers is 1.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $10,000 | -56.5% | 52,000 | 0.0% | 0.00% | – |
| Q3 2018 | $23,000 | +27.8% | 52,000 | +44.0% | 0.00% | – |
| Q2 2018 | $18,000 | +125.0% | 36,100 | +1144.8% | 0.00% | – |
| Q4 2017 | $8,000 | -99.6% | 2,900 | -97.6% | 0.00% | -100.0% |
| Q4 2015 | $1,893,000 | +113.7% | 120,721 | +43.7% | 0.00% | +100.0% |
| Q3 2015 | $886,000 | -36.9% | 84,028 | +50.9% | 0.00% | -33.3% |
| Q2 2015 | $1,405,000 | +12.8% | 55,700 | +24.6% | 0.00% | +50.0% |
| Q1 2015 | $1,246,000 | +27.1% | 44,700 | -16.8% | 0.00% | 0.0% |
| Q4 2014 | $980,000 | +40.8% | 53,700 | 0.0% | 0.00% | +100.0% |
| Q3 2014 | $696,000 | -20.5% | 53,700 | 0.0% | 0.00% | -50.0% |
| Q2 2014 | $876,000 | +72.8% | 53,700 | +87.1% | 0.00% | +100.0% |
| Q1 2014 | $507,000 | +25.5% | 28,700 | +71.9% | 0.00% | 0.0% |
| Q4 2013 | $404,000 | – | 16,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |